Subtype
Digestive System Carcinoma
CI-CAN-00000812Explore in graph →
2,123 active trials27 approved drugs139 evidence items
- NCIt
- C96963
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00000812Explore in graph →
Clinical trials
7,540 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (884)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00955721 | A Study of Combination of Gemcitabine, Oxaliplatin (GEMOX)-Sorafenib in Patients With Advanced Biliary Tract Cancer | terminated | Phase 1 / Phase 2 | 9 | University of MiamiOTHER | 1 | Jan 3, 2018 | clinicaltrials |
| NCT01012362 | Study of Pazopanib and Ixabepilone in Patients With Solid Tumors | terminated | Phase 1 | 31 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 28, 2017 | clinicaltrials |
| NCT00903396 | Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer | terminated | Phase 2 | 7 | Alliance for Clinical Trials in OncologyOTHER | 1 | Nov 24, 2017 | clinicaltrials |
| NCT02549755 | 11C-acetate for Treatment Response After Radiotherapy for HCC | terminated | Phase 2 | 1 | Justin SimsOTHER | 1 | Nov 22, 2017 | clinicaltrials |
| NCT00003530 | Antineoplaston Therapy in Treating Patients With Primary Liver Cancer | terminated | Phase 2 | 3 | Burzynski Research InstituteOTHER | 1 | Nov 21, 2017 | clinicaltrials |
| NCT02958163 | Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)(HepSTAR) | terminated | Phase 2 | 3 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Nov 7, 2017 | clinicaltrials |
| NCT01606124 | Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer | terminated | Phase 2 | 39 | Mayo ClinicOTHER | 1 | Oct 27, 2017 | clinicaltrials |
| NCT00003522 | Antineoplaston Therapy in Treating Patients With Cancer of the Small Intestine | terminated | Phase 2 | 1 | Burzynski Research InstituteOTHER | 1 | Sep 29, 2017 | clinicaltrials |
| NCT02585687 | Liver Perfusion MRI With Quantification of Tumoral Perfusion for Early Assessment of the Response of Antiangiogenics Treatments in Hepatocellular Carcinoma(ETAFIRM) | terminated | N/A | 28 | Hospices Civils de LyonOTHER | 1 | Sep 1, 2017 | clinicaltrials |
| NCT01740375 | Role of Esophagectomy in Complete Responders to CCRT(ESOPRESSO) | terminated | Phase 3 | 486 | Asan Medical CenterOTHER | 1 | Aug 29, 2017 | clinicaltrials |
| NCT01668017 | A Multicentre, Open Label, Phase 1 Trial in Japan of the Mitogen Activated Protein Extracellular Signal Regulated Kinase (MEK) Inhibitor Pimasertib Given Orally to Subjects With Solid Tumors as Monotherapy | terminated | Phase 1 | 26 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Aug 23, 2017 | clinicaltrials |
| NCT02821533 | Chemoembolization for Hepatocellular Carcinoma | terminated | Phase 2 | 24 | Chinese University of Hong KongOTHER | 1 | Aug 22, 2017 | clinicaltrials |
| NCT01114256 | FNA Tumor Sampling for CD137 Modulation: A Pilot Study | terminated | — | 83 | Stanford UniversityOTHER | 1 | Aug 3, 2017 | clinicaltrials |
| NCT00085410 | Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder | terminated | Phase 2 | 20 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2017 | clinicaltrials |
| NCT00787787 | Sunitinib Malate and Capecitabine in Treating Patients With Unresectable or Metastatic Liver Cancer | terminated | Phase 2 | 41 | University of WashingtonOTHER | 1 | Jun 1, 2017 | clinicaltrials |
| NCT01303159 | Endoscopic Bipolar Radiofrequency Probe (ENDOHPB) in the Management of Unresectable Bile Duct and Pancreatic Cancer | terminated | N/A | 29 | Weill Medical College of Cornell UniversityOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT02202759 | A Study of MLN0264 in Participants With Cancer of the Stomach or Gastroesophageal Junction | terminated | Phase 2 | 38 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT02202785 | A Study of MLN0264 in Patients With Pancreatic Cancer | terminated | Phase 2 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 4 | May 15, 2017 | clinicaltrials |
| NCT00948688 | Vorinostat With XRT and 5-FU for Locally Advanced Adenocarcinoma of the Pancreas | terminated | Phase 1 / Phase 2 | 10 | Massachusetts General HospitalOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01005875 | Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma(RAD 0901) | terminated | N/A | 5 | University of Alabama at BirminghamOTHER | 1 | May 10, 2017 | clinicaltrials |
| NCT01942083 | A Phase I, Open Label, Non Randomized, Multicenter, Dose Escalation Clinical Study to Investigate Safety and Tolerability of OPB(Otsuka Pharmaceutical Biwa)-111077 in Subjects With Advanced HCC(Hepatocellular Carcinoma) | terminated | Phase 1 | 33 | Korea Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | May 9, 2017 | clinicaltrials |
| NCT01379521 | Safety and Efficacy of RAD001 + TACE in Localized Unresectable HCC(TRACER) | terminated | Phase 2 | 65 | Novartis PharmaceuticalsINDUSTRY | 3 | May 3, 2017 | clinicaltrials |
| NCT00455091 | A Phase III Study in Post-operative HBV-related Hepatocellular Carcinoma | terminated | — | 117 | National Health Research Institutes, TaiwanOTHER | 1 | Apr 28, 2017 | clinicaltrials |
| NCT01171482 | Comparison Study of Sorafenib and 5-fluorouracil/Mitomycin for Metastatic Hepatocellular Carcinoma | terminated | Phase 2 | 5 | Seoul National University HospitalOTHER | 1 | Apr 26, 2017 | clinicaltrials |
| NCT01849588 | HCV-RNA Kinetics During Sorafenib for Hepatocellular Carcinoma (HCC) | terminated | Phase 4 | 3 | Massachusetts General HospitalOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT02819869 | The Combination Effect of Statin Plus Metformin on Relapse-free | terminated | Phase 2 | 3 | Taipei Medical University WanFang HospitalOTHER | 1 | Apr 19, 2017 | clinicaltrials |
| NCT03026803 | A Study of Oxaliplatin and Capecitabine in Unresectable Metastatic Hepatocellular Cancer | terminated | Phase 2 | 4 | City of Hope Medical CenterOTHER | 1 | Apr 13, 2017 | clinicaltrials |
| NCT01229111 | Cediranib Maleate and Combination Chemotherapy in Treating Patients With Advanced Biliary Cancers | terminated | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 1 | Mar 29, 2017 | clinicaltrials |
| NCT02391038 | MLN0264 in Previously Treated Asian Participants With Advanced Gastrointestinal Carcinoma or Metastatic or Recurrent Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Guanylyl Cyclase C | terminated | Phase 1 | 12 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Mar 29, 2017 | clinicaltrials |
| NCT01405573 | Sorafenib in First-line Treatment of Advanced B Child Hepatocellular Carcinoma(BOOST) | terminated | Phase 3 | 35 | National Cancer Institute, NaplesOTHER | 1 | Mar 28, 2017 | clinicaltrials |
| NCT00907166 | A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients | terminated | Phase 1 / Phase 2 | 6 | Cornerstone PharmaceuticalsINDUSTRY | 1 | Mar 21, 2017 | clinicaltrials |
| NCT02323906 | Safety and Efficacy Study of CC-122 Combined With Sorafenib for Primary Liver Cancer | terminated | Phase 1 | 12 | CelgeneINDUSTRY | 1 | Mar 20, 2017 | clinicaltrials |
| NCT00361244 | SU011248 in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Stage IV Colorectal Cancer | terminated | Phase 1 / Phase 2 | 6 | Massachusetts General HospitalOTHER | 1 | Feb 17, 2017 | clinicaltrials |
| NCT00576056 | Effectiveness and Safety Study of TACE Plus Oral Sorafenib for Unresectable HCC | terminated | Phase 2 | 19 | University of PittsburghOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02273752 | Pharmacokinetically Guided Everolimus in Patients With Breast Cancer, Pancreatic Neuroendocrine Tumors, or Kidney Cancer | terminated | Phase 2 | 2 | Emory UniversityOTHER | 1 | Feb 3, 2017 | clinicaltrials |
| NCT01163526 | Perfusion CT as a Predictor of Treatment Response in Patients With Hepatic Malignancies | terminated | — | 13 | Stanford UniversityOTHER | 1 | Jan 30, 2017 | clinicaltrials |
| NCT02319200 | Primary Prevention Hepatocellular Carcinoma by Metformin(METFOVIR) | terminated | Phase 3 | 11 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | Jan 11, 2017 | clinicaltrials |
| NCT00427973 | AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer | terminated | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | Oct 31, 2016 | clinicaltrials |
| NCT01123473 | Epirubicin Hydrochloride, Cisplatin, and Fluorouracil or Capecitabine With or Without Lapatinib Ditosylate as First-Line Therapy in Treating Patients With Stomach Cancer or Gastroesophageal Junction Cancer | terminated | Phase 2 | 29 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 3 | Oct 12, 2016 | clinicaltrials |
| NCT01829971 | A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection | terminated | Phase 1 | 155 | Mirna Therapeutics, Inc.INDUSTRY | 2 | Sep 27, 2016 | clinicaltrials |
| NCT01937715 | A Study Of PF-05212384 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI In Metastatic Colorectal Cancer | terminated | Phase 1 / Phase 2 | 18 | PfizerINDUSTRY | 3 | Aug 18, 2016 | clinicaltrials |
| NCT01151761 | Phase II SBRT & Chemo for Unresectable Cholangiocarcinoma Followed by Liver Transplantation | terminated | Phase 2 | 2 | Stanford UniversityOTHER | 1 | Jul 29, 2016 | clinicaltrials |
| NCT01020812 | Combination SBRT With TACE for Unresectable Hepatocellular Carcinoma | terminated | Phase 1 / Phase 2 | 11 | Stanford UniversityOTHER | 1 | Jul 27, 2016 | clinicaltrials |
| NCT01888965 | Maintenance Dovitinib for Colorectal and Pancreas Cancer | terminated | Phase 2 | 9 | Georgetown UniversityOTHER | 1 | Jul 19, 2016 | clinicaltrials |
| NCT01111292 | Inositol in Preventing Colorectal Cancer in Patients With Colitis-Associated Dysplasia | terminated | Phase 1 / Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Jul 12, 2016 | clinicaltrials |
| NCT00767234 | Permission to Collect Blood Over Time for Research | terminated | — | 104 | Stanford UniversityOTHER | 1 | Jul 11, 2016 | clinicaltrials |
| NCT01843452 | Phase II Study of Concomitant Intensity-modulated Radiotherapy Combined to Capecitabine, Mitomycin and Panitumumab in Patients With Stage II-IIIB Squamous-cell Carcinoma of the Anal Canal | terminated | Phase 2 | 8 | Centre Hospitalier Universitaire VaudoisOTHER | 1 | May 19, 2016 | clinicaltrials |
| NCT01233544 | Radiofrequency Ablation Versus Stereotactic Radiotherapy in Colorectal Liver Metastases(RAS01) | terminated | Phase 3 | 300 | University of AarhusOTHER | 2 | May 12, 2016 | clinicaltrials |
| NCT01483638 | Axitinib as Maintenance Treatment in Patients With Metastatic CRC(TTD-11-01) | terminated | Phase 2 | 84 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | May 12, 2016 | clinicaltrials |
| NCT00971126 | Study of Sorafenib With Combination of Thalidomide in Hepatocellular Carcinoma (HCC) | terminated | Phase 1 / Phase 2 | 3 | National Health Research Institutes, TaiwanOTHER | 1 | May 4, 2016 | clinicaltrials |
Data updated 23 days agoSource updated Jan 3, 2018source: clinicaltrials